Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 2/2010

01-06-2010 | Urology - Original Paper

Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis

Authors: Omer Kutlu, Erdem Akkaya, Ismail Turker Koksal, Ibrahim Cumhur Bassorgun, Mehmet Akif Ciftcioglu, Salih Sanlioglu, Erdal Kukul

Published in: International Urology and Nephrology | Issue 2/2010

Login to get access

Abstract

Introduction

Although interstitial cystitis is an inflammatory disease, its etiopathogenesis is not clearly understood. The objective of the present study is to investigate the distribution of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in bladder biopsy samples of patients diagnosed with interstitial cystitis and the role of TRAIL in the pathogenesis of interstitial cystitis.

Materials and methods

TRAIL and its receptors were stained immunohistochemically in bladder biopsy samples of 27 patients diagnosed with interstitial cystitis, and the samples were evaluated independently by two pathologists and were scored in terms of expression intensity and distribution.

Results

An evaluation of the results of the statistical analysis showed that the TRAIL-R4 receptor was immunohistochemically stained with a higher score than TRAIL-R1, TRAIL-R2, TRAIL-R3 receptors and TRAIL, with a statistically significant difference (P < 0.05).

Conclusion

These findings indicate that TRAIL-R4 is the predominant receptor in the interstitial cystitis inflammation.
Literature
1.
Hanno PM, Landis JR, Matthews-Cook Y et al (1999) The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol 161(2):553–557CrossRefPubMed
2.
Oravisto KJ (1975) Epidemiology of interstitial cystitis. Ann Chir Gynaecol Fenn 64:75–77PubMed
3.
Curhan GC, Speizer FE, Hunter DJ (1999) Epidemiology of interstitial cystitis: a population based study. J Urol 161(2):549–552CrossRefPubMed
4.
Leppilahti M, Tammela TL, Huhtala H et al (2002) Prevalence of symptoms related to interstitial cystitis in women: a population based study in Finland. J Urol 168(1):139–143CrossRefPubMed
5.
O’Leary MP, Sant GR, Fowler FJ Jr et al (1997) The interstitial cystitis symptom index and problem index. Urology 49(5A):58–63CrossRefPubMed
6.
Shea-O’Malley CC, Sant GR (1999) Quality of life in interstitial cystitis. Urol Intregrada Invest 4:303–306
7.
Parsons CL, Lilly JD, Stein P (1991) Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol 145(4):732–735PubMed
8.
Parsons CL, Stein PC, Bidair M et al (1994) Abnormal sensitivity to intravesical potassium in interstitial cystitis and radiation cystitis. Neurourol Urodyn 13(5):515–520CrossRefPubMed
9.
Parsons CL, Forrest J, Nickel JC et al (2002) Elmiron Study Group. Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology 59(3):329–333CrossRefPubMed
10.
Lewis SA, Diamond JM (1976) Na+ transport by rabbit urinary bladder, a tight epithelium. J Membr Biol 28(1):1–40CrossRefPubMed
11.
Eldrup J, Thorup J, Nielsen SL et al (1983) Permeability and ultrastructure of human bladder epithelium. Br J Urol 55(5):488–492CrossRefPubMed
12.
Trelstad RL (1985) Glycosaminoglycans: mortar, matrix, mentor. Lab Invest 53:l–l4
13.
Cornish J, Nickel JC, Vanderwee M et al (1990) Ultrastructural visualization of human bladder mucous. Urol Res 18:263–264CrossRefPubMed
14.
15.
Gill WB, Jones KW, Ruggiero KJ (1982) Protective effects of heparin and other sulfated glycosaminoglycans on crystal adhesion to injured urothelium. J Urol 127(1):152–154PubMed
16.
Parsons CL, Mulholland SG, Anwar H (1979) Antibacterial activity of bladder surface mucin duplicated by exogenous glycosaminoglycan (heparin). Infect Immun 24(2):552–557PubMed
17.
Hohlbrugger G (1995) The vesical blood-urine barrier: a relevant and dynamic interface between renal function and nervous bladder control. J Urol 154(1):6–15CrossRefPubMed
18.
Hohlbrugger G, Lentsch P, Pfaller K et al (1985) Permeability characteristics of the rat urinary bladder in experimental cystitis and after overdistension. Urol Int 40(4):211–216CrossRefPubMed
19.
Saban R, Keith IM, Bjorling DE (1997) Neuropeptide-mast cell interaction in interstitial cystitis. In: Sant GR (ed) Interstitial cystitis. Lippincott–Raven, Philadelphia, pp 53–66
20.
Theoharides TC, Sant GR (1991) Bladder mast cell activation in interstitial cystitis. Semin Urol 9(2):74–87PubMed
21.
Theoharides TC, Pang X, Letourneau R et al (1998) Interstitial cystitis: a neuroimmunoendocrine disorder. Ann NY Acad Sci 840:619–634CrossRefPubMed
22.
Abdel-Mageed AB, Ghoniem GM (1998) Potential role of rel/nuclear factor-kappaB in the pathogenesis of interstitial cystitis. J Urol 160(6):2000–2003CrossRefPubMed
23.
Nazif O, Teichman JM, Gebhart GF (2007) Neural upregulation in interstitial cystitis. Urology 69(4):24–33CrossRefPubMed
24.
Sadhukhan PC, Tchetgen MB, Rackley RR et al (2002) Sodium pentosan polysulfate reduces urothelial responses to inflammatory stimuli via an indirect mechanism. J Urol 168(1):289–292CrossRefPubMed
25.
Nesterov A, Lu X, Johnson M et al (2001) Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276(14):10767–10774CrossRefPubMed
26.
Degli-Esposti MA, Dougall WC, Smolak PJ et al (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7(6):813–820CrossRefPubMed
27.
Wiley SR, Schooley K, Smolak PJ et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 6:673–682CrossRef
28.
Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA et al (2003) Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol 4(3):255–260CrossRefPubMed
29.
Wang XC, Saban R, Kaysen JH et al (2000) Nuclear factor kappa B mediates lipopolysaccharide-induced inflammation in the urinary bladder. J Urol 163(3):993–998CrossRefPubMed
30.
Lynes WL, Flynn SD, Shortliffe LD et al (1987) Mast cell involvement in interstitial cystitis. J Urol 138:746–752PubMed
31.
Berent-Maoz B, Piliponsky AM, Daigle I et al (2006) Human mast cells undergo TRAIL-induced apoptosis. J Immunol 176(4):2272–2278PubMed
32.
Renshaw SA, Parmar JS, Singleton V et al (2003) Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 170(2):1027–1033PubMed
33.
Zamai L, Ahmad M, Bennett IM et al (1998) Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 188(12):2375–2380CrossRefPubMed
34.
Sedger LM, Glaccum MB, Schuh JC et al (2002) Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 32(8):2246–2254CrossRefPubMed
35.
Ludwig AT, Moore JM, Luo Y et al (2004) Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 64(10):3386–3390CrossRefPubMed
36.
Kimberley FC, Screaton GR (2004) Following a TRAIL: update on a ligand and its five receptors. Cell Res 14(5):359–372CrossRefPubMed
37.
Hu WH, Johnson H, Shu HB (1999) Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 274(43):30603–30610CrossRefPubMed
38.
Koksal IT, Sanlioglu AD, Karacay B et al (2008) Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol Oncol 26(2):158–165PubMed
39.
Sanlioglu AD, Koksal IT, Ciftcioglu A et al (2007) Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J Urol 177(1):359–364CrossRefPubMed
40.
Griffith TS, Anderson RD, Davidson BL et al (2000) Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 165(5):2886–2894PubMed
41.
Takayanagi H, Juji T, Miyazaki T et al (1999) Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest 104(2):137–146CrossRefPubMed
42.
Terzioglu E, Bisgin A, Sanlioglu AD et al (2007) Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatology (Oxford) 46(5):783–789CrossRef
43.
Sanlioglu AD, Koksal IT, Karacay B et al (2006) Adenovirus-mediated IKKβ expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther 13(1):21–31CrossRefPubMed
44.
Franco AV, Zhang XD, Van Berkel E et al (2001) The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 166(9):5337–5345PubMed
45.
Lamhamedi-Cherradi SE, Zheng SJ, Tisch RM et al (2003) Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes 52:2274–2278CrossRefPubMed
46.
Sato K, Nakaoka T, Yamashita N et al (2005) TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J Immunol 174:4025–4033PubMed
47.
Dirice E, Sanlioglu AD, Kahraman S et al. (2009) Adenovirus mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in STZ-induced diabetic rats. Hum Gene Ther doi:10.​1089/​hum.​2009.​039
Metadata
Title
Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis
Authors
Omer Kutlu
Erdem Akkaya
Ismail Turker Koksal
Ibrahim Cumhur Bassorgun
Mehmet Akif Ciftcioglu
Salih Sanlioglu
Erdal Kukul
Publication date
01-06-2010
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2010
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-009-9632-z

Other articles of this Issue 2/2010

International Urology and Nephrology 2/2010 Go to the issue

Urology - Original Paper

Patient awareness of smoking as a risk factor for bladder cancer

Nephrology - Editorial

Incidence of end-stage renal disease in the elderly: a steadily rising global socioeconomic epidemic

Urology - Original Paper

Impact of Charlson’s comorbidity index on overall survival following tumor nephrectomy for renal cell carcinoma

Nephrology – Original Paper

Peritoneal dialysis in the nursing home

Urology - Original Paper

Evaluation of routine application of P504S, 34βE12 and p63 immunostaining on 250 prostate needle biopsy specimens

Urology - Original Paper

Modified ureteroneocystostomy in kidney transplantation to facilitate endoscopic management of subsequent urological complications
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits